Results 61 to 70 of about 27,791 (179)

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

2,5-Dimethoxy-4-iodoamphetamine (DOI) Inhibits ∆9-Tetrahydrocannabinol-Induced Catalepsy-Like Immobilization in Mice

Journal of Pharmacological Sciences, 2007
The effect of the serotonin 5-HT2A/2C-receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) on ∆9-tetrahydrocannabinol (THC)-induced catalepsy-like immobilization was studied in mice.
Nobuaki Egashira, Emi Koushi, Kenichi Mishima, Katsunori Iwasaki, Ryozo Oishi, Michihiro Fujiwara   +5 more
doaj   +1 more source

5-HT2a receptor in mPFC influences context-guided reconsolidation of object memory in perirhinal cortex [PDF]

, 2018
Context-dependent memories may guide adaptive behavior relaying in previous experience while updating stored information through reconsolidation. Retrieval can be triggered by partial and shared cues.
Bekinschtein, Pedro Alejandro, Gallo, Francisco Tomás, Miranda, Magdalena, Morici, Juan Facundo, Weisstaub, Noelia V., Zanoni Saad, María Belén   +5 more
core   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug [PDF]

, 2014
Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently
BERSANI, FRANCESCO SAVERIO, BERSANI, Giuseppe, Eduardo Cinosi, Fabrizio Schifano, Flaminia Bolzan Mariotti Posocco, Gabriella Albano, Giovanni Martinotti, Giuseppe Valeriani, Ornella Corazza, Pierluigi Simonato, Rita Santacroce   +10 more
core   +5 more sources

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Atypical sympathomimetic drug lerimazoline mediates contractile effects in rat aorta predominantly by 5-HT2A receptors

Biomolecules & Biomedicine, 2017
Lerimazoline is a sympathomimetic drug that belongs to the imidazoline class of compounds, and is used as a nasal decongestant. Studies on lerimazoline are rare, and its pharmacological profile is not completely understood.
Eldina Rizvić, Goran Janković, Slađana Kostić-Rajačić, Miroslav M. Savić   +3 more
doaj   +1 more source

The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines [PDF]

, 2018
Classic psychedelics are substances of paramount cultural and neuroscientific importance. A distinctive feature of psychedelic drugs is the wide range of potential subjective effects they can elicit, known to be deeply influenced by the internal state of
Erowid, Earth, Erowid, Fire, Martínez Vivot, Rocío, Pallavicini, Carla, Sanz, Camila, Tagliazucchi, Enzo Rodolfo, Zamberlan, Federico   +6 more
core   +2 more sources

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Predicted Structures and Dynamics for Agonists and Antagonists Bound to Serotonin 5-HT2B and 5-HT2C Receptors [PDF]

, 2011
Subtype 2 serotonin (5-hydroxytryptamine, 5-HT) receptors are major drug targets for schizophrenia, feeding disorders, perception, depression, migraines, hypertension, anxiety, hallucinogens, and gastrointestinal dysfunctions.' We report here ...
Abrol, Ravinder, Goddard, William A., III, Heo, Jiyoung, Kim, Soo-Kyung, Li, Youyong   +4 more
core   +2 more sources